Enhertu-话题@MedSci

#Enhertu#

15篇内容 | 876人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1703561, encodeId=59481e0356179, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=阿斯利康和第一三共制药的Enhertu在美国获批用于早期治疗乳腺癌, objectType=article, longId=726473, objectId=c6fee264732d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6fee264732d, replyNumber=0, likeNumber=44, createdTime=2022-05-15, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6fee264732d, moduleTitle=阿斯利康和第一三共制药的Enhertu在美国获批用于早期治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6fee264732d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2118786, encodeId=5ece2118e862e, content=<a href='/topic/show?id=897f10555688' target=_blank style='color:#2F92EE;'>#德喜曲妥珠单抗#</a>（<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>，<a href='/topic/show?id=2f1862e434' target=_blank style='color:#2F92EE;'>#DS-8201#</a>）II期临床数据在泛HER2表达晚期<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>的持久反应，Enhertu（5.4mg/kg）治疗HER2表达肿瘤的疗效和安全性，包括<a href='/topic/show?id=a9ef83546d6' target=_blank style='color:#2F92EE;'>#胆道癌#</a>、<a href='/topic/show?id=843a85e9421' target=_blank style='color:#2F92EE;'>#膀胱癌#</a>、<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a>、<a href='/topic/show?id=942b4516096' target=_blank style='color:#2F92EE;'>#子宫内膜癌#</a>、<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>、<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a>和罕见肿瘤。<a href='/topic/show?id=e0df9e832a7' target=_blank style='color:#2F92EE;'>#阿斯利康#</a>和<a href='/topic/show?id=446ae5737da' target=_blank style='color:#2F92EE;'>#第一三共#</a>会收获很多，<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>大概率会批准Enhertu为HER2阳性<a href='/topic/show?id=fdfe10555ef9' target=_blank style='color:#2F92EE;'>#泛癌肿适应症#</a>！这就牛了，是<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>第一个靶向药物。, objectTitle=德喜曲妥珠单抗（Enhertu）II期临床数据在泛HER2表达晚期实体瘤的持久反应（DESTINY-PanTumor02研究）, objectType=article, longId=762351, objectId=656ce623519a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/c366160a3bd44df480b7eb8f2aa7eb36.jpg, objectUrl=/article/show_article.do?id=656ce623519a, replyNumber=1, likeNumber=132, createdTime=2023-03-11, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=656ce623519a, moduleTitle=德喜曲妥珠单抗（Enhertu）II期临床数据在泛HER2表达晚期实体瘤的持久反应（DESTINY-PanTumor02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=656ce623519a)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1703562, encodeId=c0671e0356263, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=NEJM：新型HER2-ADC Enhertu打破HER2低表达的乳腺癌治疗困境（DESTINY-Breast04）, objectType=article, longId=728825, objectId=0933e28825b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0933e28825b2, replyNumber=0, likeNumber=55, createdTime=2023-01-18, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0933e28825b2, moduleTitle=NEJM：新型HER2-ADC Enhertu打破HER2低表达的乳腺癌治疗困境（DESTINY-Breast04）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0933e28825b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703557, encodeId=962e1e03557b9, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%, objectType=article, longId=217554, objectId=e59521e554a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59521e554a3, replyNumber=0, likeNumber=31, createdTime=2022-02-11, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59521e554a3, moduleTitle=ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59521e554a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703559, encodeId=bd321e035595b, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=阿斯利康/第一三共的 Enhertu 在 HER2低表达的乳腺癌研究中取得成功, objectType=article, longId=299790, objectId=57fa299e9037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57fa299e9037, replyNumber=0, likeNumber=42, createdTime=2022-03-29, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57fa299e9037, moduleTitle=阿斯利康/第一三共的 Enhertu 在 HER2低表达的乳腺癌研究中取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57fa299e9037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703560, encodeId=8a551e035603e, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=FDA授予Enhertu在肺癌中的优先审查权, objectType=article, longId=724834, objectId=31b5e2483451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31b5e2483451, replyNumber=0, likeNumber=49, createdTime=2022-09-13, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31b5e2483451, moduleTitle=FDA授予Enhertu在肺癌中的优先审查权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31b5e2483451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703558, encodeId=45101e03558f4, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=35, createdTime=2022-03-30, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703555, encodeId=3f5f1e03555fe, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌, objectType=article, longId=205839, objectId=b9a4205839dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a4205839dd, replyNumber=0, likeNumber=42, createdTime=2021-03-15, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a4205839dd, moduleTitle=美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a4205839dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703556, encodeId=5aeb1e0355622, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, objectType=article, longId=206512, objectId=763d20651203, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=763d20651203, replyNumber=0, likeNumber=36, createdTime=2021-04-30, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=763d20651203, moduleTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=763d20651203)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703553, encodeId=ce6e1e035532b, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=194432, objectId=19de1944327b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19de1944327b, replyNumber=0, likeNumber=47, createdTime=2020-05-19, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19de1944327b, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19de1944327b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703549, encodeId=9c0b1e0354970, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=38, createdTime=2020-05-24, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703551, encodeId=bcd01e0355149, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=HER2阳性乳腺癌又一ADC药物Enhertu，在中国申请临床试验, objectType=article, longId=192396, objectId=3bae1923961d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bae1923961d, replyNumber=0, likeNumber=38, createdTime=2020-07-24, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bae1923961d, moduleTitle=HER2阳性乳腺癌又一ADC药物Enhertu，在中国申请临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bae1923961d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703550, encodeId=98821e0355033, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, objectType=article, longId=190853, objectId=1643190853f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1643190853f0, replyNumber=0, likeNumber=34, createdTime=2020-05-25, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1643190853f0, moduleTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1643190853f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703554, encodeId=83ba1e03554a6, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, objectType=article, longId=197261, objectId=e32219e26199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e32219e26199, replyNumber=0, likeNumber=41, createdTime=2021-02-18, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e32219e26199, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e32219e26199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1703552, encodeId=a6701e0355252, content=<a href='/topic/show?id=aaf66e9716' target=_blank style='color:#2F92EE;'>#Enhertu#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=29, createdTime=2021-02-24, rootId=0, userName=lhlxtx, userId=4e1e30523525, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Enhertu

2020-05-29

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

阿斯利康和第一三共制药的Enhertu在美国获批用于早期治疗乳腺癌

2022-05-15

showtest (审核中...)

前往app查看评论内容

全文收起 #德喜曲妥珠单抗#（#Enhertu#，#DS-8201#）II期临床数据在泛HER2表达晚期#实体瘤#的持久反应，Enhertu（5.4mg/kg）治疗HER2表达肿瘤的疗效和安全性，包括#胆道癌#、#膀胱癌#、#宫颈癌#、#子宫内膜癌#、#卵巢癌#、#胰腺癌#和罕见肿瘤。#阿斯利康#和#第一三共#会收获很多，#FDA#大概率会批准Enhertu为HER2阳性#泛癌肿适应症#！这就牛了，是#HER2阳性#第一个靶向药物。

德喜曲妥珠单抗（Enhertu）II期临床数据在泛HER2表达晚期实体瘤的持久反应（DESTINY-PanTumor02研究）

2023-03-11发表于上海

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

NEJM：新型HER2-ADC Enhertu打破HER2低表达的乳腺癌治疗困境（DESTINY-Breast04）

2023-01-18

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

ADC药物大展拳脚！突破性III期数据显示：Enhertu可降低HER2阳性转移性乳腺癌患者进展或死亡风险72%

2022-02-11

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

阿斯利康/第一三共的 Enhertu 在 HER2低表达的乳腺癌研究中取得成功

2022-03-29

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

FDA授予Enhertu在肺癌中的优先审查权

2022-09-13

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2022-03-30

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

美国FDA批准阿斯利康和第一三共制药的Enhertu用于胃腺癌

2021-03-15

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性

2021-04-30

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2020-05-19

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2020-05-24

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

HER2阳性乳腺癌又一ADC药物Enhertu，在中国申请临床试验

2020-07-24

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌

2020-05-25

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

靶向HER2的抗体药物偶联物ENHERTU治疗乳腺癌，获得欧洲药品管理局的快速审查

2021-02-18

lhlxtx (审核中...)

前往app查看评论内容

#Enhertu#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2021-02-24

科室
- - 订阅+
  - 更多科室
工具
服务